Melting point	233-235 ºC
Specific optical rotation	-34.5 º (c=2, H2O)

SDS/MSDS	S24/25

Source	SDS/MSDS Samples
Sigma-Aldrich	View & Download
TCI	View & Download
Matrix	View & Download

Synthetic Route

More

Name	CAS

More

Articles

Peer-Reviewed Papers

Existence of two parallel mechanisms for glucose uptake in heterotrophic plant cellsEtxeberria Ed, et al. Journal of Experimental Botany, 56(417), 1905-1912 (2005) High fat diet induces microbiota-dependent silencing of enteroendocrine cells.Lihua Ye et al.eLife, 8 (2019-12-04) Secretin release after Roux-en-Y gastric bypass reveals a population of glucose-sensitive S cells in distal small intestine.Ida M Modvig et al.International journal of obesity (2005), 44(9), 1859-1871 (2020-02-06) Phloridzin, an Apple Polyphenol, Exerted Unfavorable Effects on Bone and Muscle in an Experimental Model of Type 2 Diabetes in RatsLondzin P, et al. Nutrients, 10(11), 1701-1701 (2018) Proinsulin-producing, hyperglycemia-induced adipose tissue macrophages underlie insulin resistance in high fat-fed diabetic mice.Eric Dale Buras et al.FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 29(8), 3537-3548 (2015-05-09) Controlling transgene expression in subcutaneous implants using a skin lotion containing the apple metabolite phloretin.Marc Gitzinger et al.Proceedings of the National Academy of Sciences of the United States of America, 106(26), 10638-10643 (2009-06-25) Bioavailability of phloretin and phloridzin in rats.Crespy V, et al. The Journal of Nutrition, 131(12), 3227-3230 (2001) Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic ratsMalatiali S, et al. Experimental Diabetes Research, 2008 (2008) Cardioprotective potential of an SGLT2 inhibitor against doxorubicin-induced heart failureOh CM, et al. Korean circulation journal, 49 (2018) Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure.Chang Myung Oh et al.Korean circulation journal, 49(12), 1183-1195 (2019-08-29)

Remarks